Insulet Co. (NASDAQ:PODD) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have received an average rating of “Moderate Buy” from the fifteen research firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $253.27.

A number of analysts have commented on the stock. Piper Sandler boosted their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Barclays increased their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Citigroup boosted their price objective on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Finally, BTIG Research raised their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

Insulet Price Performance

Shares of PODD opened at $262.93 on Friday. Insulet has a one year low of $160.19 and a one year high of $279.40. The stock’s fifty day moving average is $241.32 and its 200-day moving average is $210.77. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market capitalization of $18.44 billion, a price-to-earnings ratio of 45.02, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bessemer Group Inc. lifted its position in shares of Insulet by 168.4% in the 1st quarter. Bessemer Group Inc. now owns 1,715 shares of the medical instruments supplier’s stock valued at $294,000 after acquiring an additional 1,076 shares in the last quarter. BOKF NA lifted its holdings in shares of Insulet by 28.5% in the first quarter. BOKF NA now owns 9,702 shares of the medical instruments supplier’s stock valued at $1,631,000 after purchasing an additional 2,154 shares in the last quarter. Grandeur Peak Global Advisors LLC boosted its position in shares of Insulet by 6.2% in the first quarter. Grandeur Peak Global Advisors LLC now owns 44,607 shares of the medical instruments supplier’s stock worth $7,646,000 after buying an additional 2,615 shares during the period. Motley Fool Asset Management LLC boosted its position in shares of Insulet by 7.1% in the first quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock worth $239,000 after buying an additional 93 shares during the period. Finally, Tidal Investments LLC grew its holdings in shares of Insulet by 58.8% during the first quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock valued at $697,000 after buying an additional 1,504 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.